查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1771576

性行为感染分子诊断市场规模、份额、趋势分析报告：按产品、应用、技术、地区、细分市场预测，2025-2033

Molecular Diagnostics For STD Market Size, Share & Trends Analysis Report By Product, By Application, By Technology, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格

性行为感染传染病分子诊断市场摘要

2024 年全球性行为感染传染病 (STD) 分子诊断市场规模估计为 33.6 亿美元，预计到 2030 年将达到 69.4 亿美元，2025 年至 2033 年期间的复合年增长率为 8.35%。披衣菌感染、淋病、梅毒和人类乳突病毒 (HPV) 等性行为感染传染病的盛行率不断上升是推动市场成长的关键因素。

精准早期检测的需求推动了分子诊断工具的普及。核酸扩增技术的进步以及人们对定期性传染病（STD）筛检的日益重视也推动了市场扩张。为了顺应这一趋势，诊断开发人员正专注于下一代分子检测，以实现对性行为感染疾病病原体的快速、多重和高通量检测。最近的创新包括照护现场核酸增幅检查和基于PCR的可携式设备，旨在在最短时间内提供准确的结果。例如，2025年3月，Visby Medical公司的女性性健康检测产品获得了美国食品药物管理局（FDA）的从头许可，这是第一个核准用于家庭使用的商用PCR诊断设备。这款手掌大小的设备能够快速可靠地检测披衣菌感染、淋病和滴虫病，30分钟内即可得出结果，无需实验室处理。这些进步反映了市场对扩大可靠检测管道、缩短诊断週转时间以及透过早期精准检测加强患者管理的关注。

此外，分子诊断研究的技术进步促进了更灵敏、更特异性传染感染（性行为感染）检测方法的发展。检测设计、样本处理和扩增技术的创新提高了诊断准确性，并减少了假阴性，这对于有效的疾病管理至关重要。这些进步有助于应对检测无症状性感染和合併感染方面的现有挑战，尤其是在高风险族群中。此外，诊断设备製造商和公共卫生机构持续的研究投入正在帮助拓展分子诊断产品线，并促进其在各种医疗保健环境中的更广泛应用。

儘管性传染病分子诊断市场不断取得进展，但仍面临许多挑战，这些挑战可能会限制其成长。新型分子诊断检测的开发、检验和监管核准需要大量的时间和资源，製造商必须遵守严格的安全和性能标准。这些因素可能会延迟产品上市并限制市场供应。此外，确保持续获得诊断技术在后勤方面也极具挑战性，尤其是在医疗基础设施有限的地区。可靠的样本储存、运输和熟练的人员配置使得在偏远和服务欠缺地区进行检测变得复杂。这些挑战凸显了我们需要齐心协力，克服监管障碍，改善分销网络，以在全球范围内扩大性传染病分子诊断的可及性。

目录

第一章调查方法与范围

第二章执行摘要

第三章性行为感染传染病（STD）分子诊断市场的变数、趋势与范围

  • 市场介绍/电网展望
  • 市场规模和成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 性行为感染传染病（STD）分子诊断市场的分析工具
    • 波特分析
    • PESTEL分析

第四章。性行为感染传染病（STD）分子诊断市场：按产品的估计和趋势分析

  • 细分仪表板
  • 性行为感染传染病（STD）分子诊断市场：2024 年及 2033 年各产品差异分析
  • 设备和服务
  • 耗材（试剂和套件）
  • 软体

第五章。性行为感染传染病（STD）分子诊断市场：按应用的估计和趋势分析

  • 细分仪表板
  • 性行为感染传染病（STD）分子诊断市场：2024 年和 2033 年应用趋势分析
  • CT/NG检查
  • 梅毒检测
  • 淋病检测
  • HSV侦测
  • HPV检测
  • HIV检测
  • 滴虫
  • 脲原体+霉浆菌
  • 其他的

第六章。性行为感染传染病（STD）分子诊断市场：按技术进行的估计和趋势分析

  • 细分仪表板
  • 性行为感染传染病 (STD) 分子诊断市场：2024 年和 2033 年技术趋势分析
  • 实验室测试
    • 商业/私人实验室
    • 公共卫生研究所
  • PoC 测试

第七章。性行为感染传染病（STD）分子诊断市场：按地区估计和趋势分析

  • 2024年及2033年各地区性行为感染传染病（STD）分子诊断市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • BD
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • Abbott
    • Cepheid（Danaher）
    • Qiagen
    • OraSure Technologies, Inc.
    • Bio-Rad Laboratories, Inc.
    • bioMerieux SA
    • Thermo Fisher Scientific, Inc.
    • Seegene Inc.
    • DiaSorin SpA
Product Code: GVR-4-68040-619-4

Molecular Diagnostics For STD Market Summary

The global molecular diagnostics for sexually transmitted diseases (STDs) market size was estimated at USD 3.36 billion in 2024 and is projected to reach USD 6.94 billion by 2030, growing at a CAGR of 8.35% from 2025 to 2033. The increasing incidence of sexually transmitted infections such as chlamydia, gonorrhea, syphilis, and human papillomavirus (HPV) is a key factor driving market growth.

The demand for accurate and early detection contributes to the uptake of molecular diagnostic tools. Improvements in nucleic acid amplification technologies and growing awareness about regular STD screening are also supporting market expansion. Supporting this trend, diagnostic developers are concentrating on next-generation molecular tests that offer rapid, multiplexed, and high-throughput detection of sexually transmitted pathogens. Recent innovations include point-of-care nucleic acid amplification tests and portable PCR-based devices designed to deliver accurate results in minimal time. For instance, in March 2025, Visby Medical received U.S. Food and Drug Administration (FDA) De Novo authorization for its Women's Sexual Health Test, the first over-the-counter PCR diagnostic device approved for at-home use. This palm-sized device enables rapid, reliable testing for chlamydia, gonorrhea, and trichomoniasis, providing results within 30 minutes without needing laboratory processing. Such advancements reflect the market's focus on expanding access to reliable testing, reducing diagnostic turnaround time, and enhancing patient management through early and precise detection.

Moreover, technological progress in molecular diagnostic research has enabled the development of more sensitive, specific, and targeted tests for sexually transmitted infections. Innovations in assay design, sample processing, and amplification techniques have improved diagnostic accuracy and reduced false negatives, crucial for effective disease management. These advancements help address existing challenges in detecting asymptomatic infections and co-infections, especially in high-risk populations. In addition, continued investment in research by diagnostic manufacturers and public health organizations supports the expansion of molecular diagnostics pipelines and promotes wider availability across diverse healthcare settings.

Despite ongoing progress, the molecular diagnostics for STD market faces several challenges that may limit growth. The development, validation, and regulatory approval of new molecular tests require substantial time and resources, with manufacturers needing to comply with rigorous safety and performance standards. These factors often cause delays in product launches and restrict market availability. In addition, ensuring consistent access to diagnostic technologies presents logistical difficulties, especially in regions with limited healthcare infrastructure. The need for reliable sample storage, transportation, and skilled personnel complicates test deployment in remote or underserved areas. These challenges highlight the necessity for coordinated efforts to address regulatory hurdles and improve distribution networks to expand access to molecular diagnostics for STDs worldwide.

Global Molecular Diagnostics For STDs Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics for sexually transmitted diseases (STDs) market report based on product, application, technology, and region.

  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Instruments & Services
  • Consumables (Reagents and kits)
  • Softwares
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • CT/NG Testing
  • Syphilis Testing
  • Gonorrhea Testing
  • HSV Testing
  • HPV Testing
  • HIV Testing
  • Trichomonas
  • Ureaplasma + Mycoplasma
  • Others
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Laboratory Testing
    • Commercial/Private Labs
    • Public Health Labs
  • PoC testing
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Product Movement Analysis, 2024 & 2033 (USD Million)
  • 4.3. Instruments & Services
    • 4.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Consumables (Reagents and kits)
    • 4.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Software
    • 4.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Application Movement Analysis, 2024 & 2033 (USD Million)
  • 5.3. CT/NG testing
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Syphilis testing
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Gonorrhea testing
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. HSV testing
    • 5.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. HPV testing
    • 5.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. HIV testing
    • 5.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Trichomonas
    • 5.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.10. Ureaplasma + Mycoplasma
    • 5.10.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.11. Others
    • 5.11.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Technology Movement Analysis, 2024 & 2033 (USD Million)
  • 6.3. Laboratory Testing
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.2. Commercial/Private Labs
      • 6.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.3.3. Public Health Labs
      • 6.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. PoC testing
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market: Regional Estimates & Trend Analysis

  • 7.1. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Share, By Region, 2024 & 2033, USD Million
  • 7.2. North America
    • 7.2.1. North America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. South Africa Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Molecular Diagnostics for Sexually Transmitted Diseases (STDs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. BD
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. F. Hoffmann-La Roche Ltd
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Hologic Inc.
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Abbott
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Cepheid (Danaher)
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Qiagen
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. OraSure Technologies, Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Bio-Rad Laboratories, Inc.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. bioMerieux SA
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Thermo Fisher Scientific, Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Seegene Inc.
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. DiaSorin S.p.A
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviation
  • Table 3 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 5 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 6 Global Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 7 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 9 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 10 North America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 11 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 12 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 13 U.S. Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 14 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 15 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 16 Canada Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 17 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 18 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 19 Mexico Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 20 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 22 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 23 Europe Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 24 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 25 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 26 Germany Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 27 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 28 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 29 UK Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 30 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 31 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 32 France Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 33 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 34 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 35 Italy Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 36 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 37 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 38 Spain Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 39 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 40 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 41 Denmark Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 42 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 43 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 44 Sweden Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 45 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 46 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 47 Norway Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 52 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 53 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 54 Japan Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 55 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 56 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 57 China Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 58 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 59 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 60 India Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 61 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 62 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 63 South Korea Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 64 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 65 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 66 Australia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 67 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 68 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 69 Thailand Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 70 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 72 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 73 Latin America Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 74 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 75 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 76 Brazil Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 77 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 78 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 79 Argentina Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 84 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 87 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 88 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 89 South Africa Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 90 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 91 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 92 UAE Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Product, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Application, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Molecular diagnostics for Sexually Transmitted Diseases (STDs) Market, By Technology, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market segmentation
  • Fig. 2 Data analysis models
  • Fig. 3 Market formulation and validation
  • Fig. 4 Data validating & publishing
  • Fig. 5 Market research process
  • Fig. 6 Information procurement
  • Fig. 7 Primary research
  • Fig. 8 Value-chain-based sizing & forecasting
  • Fig. 9 QFD modelling for market share assessment
  • Fig. 10 Market formulation & validation
  • Fig. 11 Commodity flow analysis
  • Fig. 12 Market outlook
  • Fig. 13 Segment snapshot-1
  • Fig. 14 Segment snapshot-2
  • Fig. 15 Competitive landscape snapshot
  • Fig. 16 Market trends & outlook
  • Fig. 17 Porter's five force analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product outlook key takeaways
  • Fig. 20 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Product movement analysis
  • Fig. 21 Instruments & Services market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Consumables (Reagents and kits) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Softwares market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application outlook key takeaways
  • Fig. 25 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Application movement analysis
  • Fig. 26 CT/NG testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Syphilis testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Gonorrhea testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 HSV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 HPV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 HIV testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Trichomonas market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Ureaplasma + Mycoplasma market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology outlook key takeaways
  • Fig. 36 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market: Technology movement analysis
  • Fig. 37 Laboratory Testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Commercial/Private Labs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Public Health Labs market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 PoC testing market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Regional marketplace outlook, 2024 & 2033 (USD million)
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 North America
  • Fig. 44 North America market estimates and forecasts, 2021 - 2033
  • Fig. 45 U.S.
  • Fig. 46 U.S. market estimates and forecasts, 2021 - 2033
  • Fig. 47 Canada
  • Fig. 48 Canada market estimates and forecasts, 2021 - 2033
  • Fig. 49 Mexico
  • Fig. 50 Mexico market estimates and forecasts, 2021 - 2033
  • Fig. 51 Europe
  • Fig. 52 Europe market estimates and forecasts, 2021 - 2033
  • Fig. 53 UK
  • Fig. 54 UK market estimates and forecasts, 2021 - 2033
  • Fig. 55 Germany
  • Fig. 56 Germany market estimates and forecasts, 2021 - 2033
  • Fig. 57 France
  • Fig. 58 France market estimates and forecasts, 2021 - 2033
  • Fig. 59 Italy
  • Fig. 60 Italy market estimates and forecasts, 2021 - 2033
  • Fig. 61 Spain
  • Fig. 62 Spain market estimates and forecasts, 2021 - 2033
  • Fig. 63 Denmark
  • Fig. 64 Denmark market estimates and forecasts, 2021 - 2033
  • Fig. 65 Sweden
  • Fig. 66 Sweden market estimates and forecasts, 2021 - 2033
  • Fig. 67 Norway
  • Fig. 68 Norway market estimates and forecasts, 2021 - 2033
  • Fig. 69 Asia Pacific
  • Fig. 70 Asia Pacific market estimates and forecasts, 2021 - 2033
  • Fig. 71 China
  • Fig. 72 China market estimates and forecasts, 2021 - 2033
  • Fig. 73 Japan
  • Fig. 74 Japan market estimates and forecasts, 2021 - 2033
  • Fig. 75 India
  • Fig. 76 India market estimates and forecasts, 2021 - 2033
  • Fig. 77 Thailand
  • Fig. 78 Thailand market estimates and forecasts, 2021 - 2033
  • Fig. 79 South Korea
  • Fig. 80 South Korea market estimates and forecasts, 2021 - 2033
  • Fig. 81 Australia
  • Fig. 82 Australia market estimates and forecasts, 2021 - 2033
  • Fig. 83 Latin America
  • Fig. 84 Latin America market estimates and forecasts, 2021 - 2033
  • Fig. 85 Brazil
  • Fig. 86 Brazil market estimates and forecasts, 2021 - 2033
  • Fig. 87 Argentina
  • Fig. 88 Argentina market estimates and forecasts, 2021 - 2033
  • Fig. 89 Middle East and Africa
  • Fig. 90 Middle East and Africa market estimates and forecasts, 2021 - 2033
  • Fig. 91 South Africa
  • Fig. 92 South Africa market estimates and forecasts, 2021 - 2033
  • Fig. 93 Saudi Arabia
  • Fig. 94 Saudi Arabia market estimates and forecasts, 2021 - 2033
  • Fig. 95 UAE
  • Fig. 96 UAE market estimates and forecasts, 2021 - 2033
  • Fig. 97 Kuwait
  • Fig. 98 Kuwait market estimates and forecasts, 2021 - 2033
  • Fig. 99 Market share of key market players-
  • Fig. 100 Market participant categorization
  • Fig. 101 Molecular diagnostics for Sexually Transmitted Diseases (STDs) market position analysis, 2024
  • Fig. 102 Strategic framework